Aspen Aerogels, Inc. (ASPN) Guidance & Earnings Results

On 2026-08-06 Aspen Aerogels, Inc. mixed guidance: "Q3 2026 revenue $65-80M; adjusted EBITDA $7-15M; net loss $6-9M; net loss per share $0.07-0.11; FY 2026 capex <$10M excluding…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ASPNAspen Aerogels, Inc.Follow ASPN — free

Building Products & Equipment · Industrials

—

Price chart with a free account

Market cap: 458.1M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 23 Feb, in 122 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
6 Aug 26	Mixed	Q3 2026 revenue $65-80M; adjusted EBITDA $7-15M; net loss $6-9M; net loss per share $0.07-0.11; FY 2026 capex <$10M excluding restoration
7 May 26	Lowered	Q2 2026 revenue guidance $40-48M (midpoint $44M) vs prior year Q2 $78M; Adj EBITDA guidance ($4)-($10)M
6 Nov 25	Lowered	FY2025 revenue guidance cut from $297-317M to $270-280M; adjusted EBITDA cut from $35-45M to $7-15M · full year
7 Aug 25	—	H2 2025 revenue $140-160M; H2 Adj. EBITDA $20-30M; H2 capex $10M; FY25 revenue $297-317M; FY25 Adj. EBITDA $35-45M; FY25 capex $25M (excl. Statesboro). · full year

Aspen Aerogels, Inc. — questions

What guidance did Aspen Aerogels, Inc. give?: On 2026-08-06: "Q3 2026 revenue $65-80M; adjusted EBITDA $7-15M; net loss $6-9M; net loss per share $0.07-0.11; FY 2026 capex <$10M excluding restoration"
When does Aspen Aerogels, Inc. report earnings?: Aspen Aerogels, Inc.'s next earnings report is expected on 2027-02-23.

Every figure on this page comes from Aspen Aerogels, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.